Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Oral antibiotics in acne: a retrospective single-centre analysis of current prescribing in primary care and its alignment with the national antibiotic quality premium.

Whitehouse H, Solman L, Eady EA, Layton AM.

Br J Dermatol. 2019 Jul 13. doi: 10.1111/bjd.18339. [Epub ahead of print] No abstract available.

PMID:
31301232
2.

Assessing effectiveness in acne clinical trials: steps towards a core outcome measure set.

Thiboutot DM, Layton AM, Chren MM, Eady EA, Tan J.

Br J Dermatol. 2019 Oct;181(4):700-706. doi: 10.1111/bjd.18011. Epub 2019 May 29. Review.

PMID:
31002382
3.

Response to 'Views of oral antibiotics and advice seeking about acne: a qualitative study of online discussion forums' based on evidence obtained from The Acne Priority Setting Partnership.

Horton E, Lee N, Layton AM, Eady EA.

Br J Dermatol. 2019 May;180(5):1265-1266. doi: 10.1111/bjd.17599. Epub 2019 Jan 24. No abstract available.

PMID:
30604870
4.

Stemming the tide of antimicrobial resistance: implications for management of acne vulgaris.

Santer M, Francis NA, Platt D, Eady EA, Layton AM.

Br J Gen Pract. 2018 Feb;68(667):64-65. doi: 10.3399/bjgp18X694457. No abstract available.

5.

AGREE II assessments of recent acne treatment guidelines: how well do they reveal trustworthiness as defined by the U.S. Institute of Medicine criteria?

Eady EA, Layton AM, Sprakel J, Arents BWM, Fedorowicz Z, van Zuuren EJ.

Br J Dermatol. 2017 Dec;177(6):1716-1725. doi: 10.1111/bjd.15777. Epub 2017 Nov 29.

PMID:
28667760
6.

Identifying What to Measure in Acne Clinical Trials: First Steps towards Development of a Core Outcome Set.

Layton AM, Eady EA, Thiboutot DM, Tan J; Acne Core Outcomes Research Network (ACORN) Outcomes Identification Group.

J Invest Dermatol. 2017 Aug;137(8):1784-1786. doi: 10.1016/j.jid.2017.04.017. Epub 2017 Apr 27. No abstract available.

7.

Prioritizing treatment outcomes: How people with acne vulgaris decide if their treatment is working.

Layton AM, Whitehouse H, Eady EA, Cowdell F, Warburton KL, Fenton M.

J Evid Based Med. 2017 Aug;10(3):163-170. doi: 10.1111/jebm.12249. Epub 2017 May 24.

PMID:
28444879
8.

Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review.

Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ.

Am J Clin Dermatol. 2017 Apr;18(2):169-191. doi: 10.1007/s40257-016-0245-x. Review.

9.

The management of acne vulgaris in primary care: a cohort study of consulting and prescribing patterns using the Clinical Practice Research Datalink.

Francis NA, Entwistle K, Santer M, Layton AM, Eady EA, Butler CC.

Br J Dermatol. 2017 Jan;176(1):107-115. doi: 10.1111/bjd.15081. Epub 2016 Dec 27.

PMID:
27716910
10.

Tert-butyl benzoquinone: mechanism of biofilm eradication and potential for use as a topical antibiofilm agent.

Ooi N, Eady EA, Cove JH, O'Neill AJ.

J Antimicrob Chemother. 2016 Jul;71(7):1841-4. doi: 10.1093/jac/dkw100. Epub 2016 Apr 27.

11.

Ineffective consultations for acne: what is important to patients?

Cowdell F, Eady EA, Layton AM, Levell NJ, Jones C, Ridd MJ.

Br J Dermatol. 2016 Oct;175(4):826-8. doi: 10.1111/bjd.14689. Epub 2016 Aug 11. No abstract available.

PMID:
27114267
12.

Identifying acne treatment uncertainties via a James Lind Alliance Priority Setting Partnership.

Layton A, Eady EA, Peat M, Whitehouse H, Levell N, Ridd M, Cowdell F, Patel M, Andrews S, Oxnard C, Fenton M, Firkins L.

BMJ Open. 2015 Jul 17;5(7):e008085. doi: 10.1136/bmjopen-2015-008085.

13.

Redox-active compounds with a history of human use: antistaphylococcal action and potential for repurposing as topical antibiofilm agents.

Ooi N, Eady EA, Cove JH, O'Neill AJ.

J Antimicrob Chemother. 2015 Feb;70(2):479-88. doi: 10.1093/jac/dku409. Epub 2014 Nov 3.

14.

A honey trap for the treatment of acne: manipulating the follicular microenvironment to control Propionibacterium acnes.

Eady EA, Layton AM, Cove JH.

Biomed Res Int. 2013;2013:679680. doi: 10.1155/2013/679680. Epub 2013 May 14.

15.

A distinct acne microbiome: fact or fiction?

Eady EA, Layton AM.

J Invest Dermatol. 2013 Sep;133(9):2294-5. doi: 10.1038/jid.2013.259. Epub 2013 Jun 12. No abstract available.

16.

Benzoyl peroxide and adapalene fixed combination: a novel agent for acne.

Layton AM, Eady EA.

Br J Dermatol. 2009 Nov;161(5):971-6. doi: 10.1111/j.1365-2133.2009.09531.x. No abstract available.

PMID:
19857206
17.

Interleukin-10 secretion from CD14+ peripheral blood mononuclear cells is downregulated in patients with acne vulgaris.

Caillon F, O'Connell M, Eady EA, Jenkins GR, Cove JH, Layton AM, Mountford AP.

Br J Dermatol. 2010 Feb 1;162(2):296-303. doi: 10.1111/j.1365-2133.2009.09420.x. Epub 2009 Jul 20.

PMID:
19796181
18.

Temporal changes in sebum excretion and propionibacterial colonization in preadolescent children with and without acne.

Mourelatos K, Eady EA, Cunliffe WJ, Clark SM, Cove JH.

Br J Dermatol. 2007 Jan;156(1):22-31.

PMID:
17199562
19.

Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne.

Coates P, Vyakrnam S, Ravenscroft JC, Stables GI, Cunliffe WJ, Leyden JJ, Johnson J, Eady EA, Cove JH.

Br J Dermatol. 2005 Dec;153(6):1126-36. Erratum in: Br J Dermatol. 2006 Apr;154(4):807.

PMID:
16307647
20.

Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial.

Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Po AL, O'Neill C, Simpson NB, Walters CE, Carnegie E, Lewis JB, Dada J, Haynes M, Williams K, Williams HC.

Lancet. 2004 Dec 18-31;364(9452):2188-95.

PMID:
15610805
21.

Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.

Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, Williams HC.

Health Technol Assess. 2005 Jan;9(1):iii-212.

22.

Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema.

Ravenscroft JC, Layton AM, Eady EA, Murtagh MS, Coates P, Walker M, Cove JH.

Br J Dermatol. 2003 May;148(5):1010-7.

PMID:
12786834
24.

Antibiotic-resistant acne: lessons from Europe.

Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Galvan Peréz Del Pulgar JI, Rollman O, Török L, Eady EA, Cove JH.

Br J Dermatol. 2003 Mar;148(3):467-78.

PMID:
12653738
25.

Propionibacterium acnes resistance: a worldwide problem.

Eady EA, Gloor M, Leyden JJ.

Dermatology. 2003;206(1):54-6. Review.

PMID:
12566805
26.

Minocycline for acne vulgaris: efficacy and safety.

Garner SE, Eady EA, Popescu C, Newton J, Li WA.

Cochrane Database Syst Rev. 2003;(1):CD002086. Review. Update in: Cochrane Database Syst Rev. 2012;8:CD002086.

PMID:
12535427
27.

Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study.

Coates P, Vyakrnam S, Eady EA, Jones CE, Cove JH, Cunliffe WJ.

Br J Dermatol. 2002 May;146(5):840-8.

PMID:
12000382
28.
29.

Is acne an infection of blocked pilosebaceous follicles? Implications for antimicrobial treatment.

Eady EA, Cove JH.

Am J Clin Dermatol. 2000 Jul-Aug;1(4):201-9. Review.

PMID:
11702364
30.

Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.

Ross JI, Snelling AM, Eady EA, Cove JH, Cunliffe WJ, Leyden JJ, Collignon P, Dréno B, Reynaud A, Fluhr J, Oshima S.

Br J Dermatol. 2001 Feb;144(2):339-46.

PMID:
11251569
31.
32.

Minocycline for acne vulgaris: efficacy and safety.

Garner SE, Eady EA, Popescu C, Newton J, Li Wan Po A.

Cochrane Database Syst Rev. 2000;(2):CD002086. Review. Update in: Cochrane Database Syst Rev. 2003;(1):CD002086.

PMID:
10796856
33.

A variety of gram-positive bacteria carry mobile mef genes.

Luna VA, Coates P, Eady EA, Cove JH, Nguyen TT, Roberts MC.

J Antimicrob Chemother. 1999 Jul;44(1):19-25.

PMID:
10459806
34.

16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium.

Ross JI, Eady EA, Cove JH, Cunliffe WJ.

Antimicrob Agents Chemother. 1998 Jul;42(7):1702-5.

35.

Inflammation in acne vulgaris: failure of skin micro-organisms to modulate keratinocyte interleukin 1 alpha production in vitro.

Ingham E, Walters CE, Eady EA, Cove JH, Kearney JN, Cunliffe WJ.

Dermatology. 1998;196(1):86-8. No abstract available.

PMID:
9557236
36.

Resistance to erythromycin and clindamycin in cutaneous propionibacteria is associated with mutations in 23S rRNA.

Ross JI, Eady EA, Cove JH, Ratyal AH, Cunliffe WJ.

Dermatology. 1998;196(1):69-70. No abstract available.

PMID:
9557230
37.

Propionibacterium acnes and acne.

Holland KT, Aldana O, Bojar RA, Cunliffe WJ, Eady EA, Holland DB, Ingham E, McGeown C, Till A, Walters C.

Dermatology. 1998;196(1):67-8. No abstract available.

PMID:
9557229
38.

Bacterial resistance in acne.

Eady EA.

Dermatology. 1998;196(1):59-66.

PMID:
9557228
39.

Cutaneous antimicrobial defense.

Cove JH, Eady EA.

Clin Dermatol. 1998 Jan-Feb;16(1):141-7. Review. No abstract available.

PMID:
9472444
40.

Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA.

Ross JI, Eady EA, Cove JH, Jones CE, Ratyal AH, Miller YW, Vyakrnam S, Cunliffe WJ.

Antimicrob Agents Chemother. 1997 May;41(5):1162-5.

41.

Benefit-risk assessment of acne therapies.

Seukeran DC, Eady EA, Cunliffe WJ.

Lancet. 1997 Apr 26;349(9060):1251-2. No abstract available.

PMID:
9130967
42.

Comparison of serum antibiotic levels in acne patients receiving the standard or a modified release formulation of minocycline hydrochloride.

Gardner KJ, Eady EA, Cove JH, Taylor JP, Cunliffe WJ.

Clin Exp Dermatol. 1997 Mar;22(2):72-6.

PMID:
9330069
43.

Does oral isotretinoin prevent Propionibacterium acnes resistance?

Coates P, Adams CA, Cunliffe WJ, McGinley KT, Eady EA, Leyden JJ, Ravenscroft J, Vyakrnam S, Vowels B.

Dermatology. 1997;195 Suppl 1:4-9; discussion 38-40. Review.

PMID:
9310739
44.
45.

Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts.

Miller YW, Eady EA, Lacey RW, Cove JH, Joanes DN, Cunliffe WJ.

J Antimicrob Chemother. 1996 Nov;38(5):829-37.

PMID:
8961052
46.

The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria.

Eady EA, Bojar RA, Jones CE, Cove JH, Holland KT, Cunliffe WJ.

Br J Dermatol. 1996 Jan;134(1):107-13.

PMID:
8745894
47.

The use of PCR to isolate a putative ABC transporter from Saccharopolyspora erythraea.

O'Neill MP, Eady EA, Radford A, Baumberg S, Cove JH.

FEMS Microbiol Lett. 1995 Sep 1;131(2):189-95.

PMID:
7557329
49.
50.

Variation in comedonal antibiotic concentrations following application of topical tetracycline for acne vulgaris.

Gardner KJ, Cunliffe WJ, Eady EA, Cove JH.

Br J Dermatol. 1994 Nov;131(5):649-54.

PMID:
7999595

Supplemental Content

Support Center